糖尿病药物的选择.pptVIP

* 而对于HDL-C这样的影响心血管疾病发病风险的非常重要的标志物，研究显示，无论是罗格列酮还是艾可拓都能升高HDL-C的水平，但是艾可拓治疗组的患者，HDL-C的上升幅度大概是罗格列酮的两倍左右。 A 24-week comparison study evaluated the effect of ACTOS with that of rosiglitazone on HDL-C levels in patients with type 2 diabetes and dyslipidemia. At baseline, mean HDL-C was 38.8 mg/dL in the ACTOS group and 39.7 mg/dL in the rosiglitazone group (P=ns). While both groups showed an increase in HDL-C at week 24, a significantly greater increase was observed in the ACTOS group than in the rosiglitazone group, with a mean percent change from baseline of 14.9% (P=0.001) (5.2 mg/dL) and 7.8%